300702SZSE
🚨 Material Event

Announcement on the Approval of a Drug by a Wholly-Owned Subsidiary

✨ AI Summary

Zhejiang Tianyu Pharmaceutical Co., Ltd. announces that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., has received approval from the NMPA for Brexpiprazole Tablets. This approval allows for domestic production and sales, expanding the company's product portfolio and potentially increasing revenue and market competitiveness. The company has invested approximately 6.00 million RMB in R&D for this drug.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300702

Securities Abbreviation: Tianyu Shares

Announcement No.: 2026-065

Zhejiang Tianyu Pharmaceutical Co., Ltd.

Announcement on the Approval of a Drug by a Wholly-Owned Subsidiary

The Board of Directors and all directors of the Company guarantee that the information contained in this announcement is free from false representations, misleading statements, or material omissions, and that they shall bear individual and joint legal responsibility for the authenticity, accuracy, and completeness of the content.

Zhejiang Tianyu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") announces that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd. (hereinafter referred to as "Nuode Pharmaceutical"), recently received the "Drug Registration Certificate" for Brexpiprazole Tablets issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). The relevant situation is hereby announced as follows:

I. Drug Information

1. Basic Drug Information

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.